An 8-year-old boy is brought to the child psychiatry clinic by his mother with complaints of difficulty concentrating in school, frequent fidgeting, and inability to sit still during class. The teacher reports that he often interrupts other children, blurts out answers before questions are completed, and frequently loses his belongings. His academic performance has declined over the past 2 years. On examination, the child is restless, makes poor eye contact, and has difficulty sustaining attention during the interview. His developmental milestones were normal, and there is no history of head injury or seizures. The mother reports similar behavioral issues since age 5 years. Which of the following is the most appropriate first-line pharmacological intervention for this child?

Explanation

## Diagnosis and First-Line Management **Key Point:** This child meets DSM-5 criteria for Attention-Deficit/Hyperactivity Disorder (ADHD), combined presentation, with symptom onset before age 12 and functional impairment across multiple settings (school, home). ## First-Line Pharmacotherapy for ADHD **High-Yield:** Stimulant medications are the first-line pharmacological treatment for ADHD in children and adolescents. Methylphenidate and amphetamines (mixed amphetamine salts) are the most effective and most studied agents. ### Methylphenidate Mechanism and Efficacy Methylphenidate is a selective norepinephrine and dopamine reuptake inhibitor that: - Increases dopamine and norepinephrine in the prefrontal cortex - Improves executive function, attention, and impulse control - Has rapid onset (30–60 minutes for immediate-release formulation) - Shows efficacy in 70–80% of children with ADHD - Available in multiple formulations (immediate-release, extended-release) **Clinical Pearl:** Extended-release methylphenidate is often preferred in clinical practice for sustained symptom control throughout the school day and improved medication adherence. ## Comparison of ADHD Pharmacotherapy Options | Agent | Class | Onset | First-Line? | Notes | |-------|-------|-------|-------------|-------| | **Methylphenidate** | Stimulant | 30–60 min | **Yes** | Gold standard; rapid effect; multiple formulations | | **Amphetamines** | Stimulant | 30–60 min | **Yes** | Equally effective; slightly longer half-life | | **Atomoxetine** | Non-stimulant SNRI | 2–4 weeks | Second-line | Slower onset; useful if stimulants contraindicated or ineffective | | **Fluoxetine** | SSRI | 4–6 weeks | No | Not indicated for ADHD; used for comorbid depression/anxiety | | **Risperidone** | Atypical antipsychotic | Variable | No | Reserved for severe aggression or comorbid psychosis; not first-line | **Mnemonic:** **SANDS** — Stimulants Are the Norm for ADHD; Drugs (non-stimulants) are Secondary. ## Monitoring and Safety - Baseline cardiovascular assessment (BP, HR, ECG if indicated) - Weight and height monitoring - Regular follow-up for efficacy and adverse effects - Appetite suppression and sleep disturbance are common but manageable side effects [cite:DSM-5, American Academy of Pediatrics ADHD Clinical Practice Guideline]